Calcitermin: natural germ-killer from human airways

What this is

Calcitermin is a 14-amino acid antimicrobial peptide isolated from human airway secretions, derived from the C-terminal region of S100A12 (also known as calgranulin C or EN-RAGE). S100A12 is a calcium-binding protein of the S100 family expressed at high levels in neutrophils and myeloid-derived cells, where it functions in innate immune activation, inflammation, and antimicrobial defense. Calcitermin represents the antimicrobial activity residing in the C-terminal domain of S100A12 — a functional activity released when the full protein is processed to smaller peptide fragments in airway fluids. The stored sequence VSISRSELDTINQK (14 aa) is the C-terminal antimicrobial fragment of the mature S100A12 protein (92 aa); S100A12 does not use the conventional ER-Golgi secretion pathway but is released through non-classical secretion during inflammation and neutrophil degranulation.

Calcitermin has antibacterial and antifungal activity against a range of pathogens relevant to pulmonary infection. It was first characterized from human bronchoalveolar lavage fluid (Cole et al. 2001), placing it in the context of airway mucosal innate defense. Calcitermin has no approved clinical use and remains a research-stage antimicrobial peptide; its biological interest lies in understanding how S100A12, a well-established neutrophil-derived inflammatory marker, also contributes to direct antimicrobial killing through its processed fragments.

History

S100A12 (calgranulin C) was characterized as a neutrophil-specific calcium-binding protein and inflammatory marker in the early 1990s. The S100 protein family is large, and S100A12 attracted attention as a serum and stool biomarker for inflammatory bowel disease, Crohn's disease, and other inflammatory conditions. Its primary characterized functions prior to the calcitermin work were as a ligand for RAGE (receptor for advanced glycation end-products), a pattern-recognition receptor mediating inflammatory amplification, and as a chemotactic and pro-inflammatory signal.

Cole and colleagues at the Salk Institute identified calcitermin in 2001 during a systematic characterization of antimicrobial peptides in human airway secretions. Using reverse-phase HPLC fractionation of bronchoalveolar lavage fluid followed by bioactivity-guided screening against bacteria and fungi, they isolated a 14-aa peptide and sequenced it by mass spectrometry and Edman degradation, identifying it as the C-terminal fragment of S100A12. The Cole and colleagues (2001) FEBS Letters paper established calcitermin as a distinct antimicrobial entity within the S100A12 protein and coined the name "calcitermin" (reflecting the calcium-binding S100 family origin and C-terminal localization).

The subsequent decade of S100A12 research was dominated by its use as a biomarker — plasma and fecal S100A12 became established markers of neutrophilic inflammation. Calcitermin's specific antimicrobial role received less attention than S100A12's receptor-biology and biomarker applications, though later work by Mishra and colleagues (2022) extended the characterization of S100A12 antimicrobial activity against clinically relevant pathogens including Pseudomonas aeruginosa biofilms.

What it does

Antibacterial activity: Calcitermin inhibits the growth of both gram-positive and gram-negative bacteria. The 2001 characterization demonstrated activity against bacteria relevant to pulmonary infection, consistent with calcitermin's location in airway secretions and its probable function as a component of mucosal innate defense. The mechanism of calcitermin's antibacterial activity is consistent with cationic antimicrobial peptide membrane disruption — the sequence contains positively charged residues (Arg⁵, Lys¹⁴) capable of interacting with negatively charged bacterial membrane phospholipids.

Antifungal activity: Calcitermin shows antifungal activity against Candida species and other medically relevant fungi. Antifungal activity is a feature shared with several other S100-family C-terminal antimicrobial peptides and with related AMPs from airway secretions. The antifungal mechanism is membrane-disruptive and does not require receptor-mediated uptake.

Context within S100A12 biology: Intact S100A12 protein (92 aa) also has antimicrobial activity against bacteria and fungi, but the isolated calcitermin fragment from the C-terminus is the form characterized in the airway context. This parallels the chromogranin A/vasostatin-1 pattern: the full-length precursor protein has structural and signaling roles, while a terminal fragment carries concentrated antimicrobial activity. S100A12's antimicrobial contribution in vivo comes from both the intact protein (released by degranulating neutrophils at inflammatory sites) and potentially from proteolytic processing to calcitermin in airway fluids.

Inhibition of Pseudomonas aeruginosa biofilm: Mishra and colleagues (2022) extended characterization of S100A12 antimicrobial activity to include inhibition of P. aeruginosa biofilm formation and pyoverdine secretion (a siderophore enabling iron acquisition). While focused on the intact S100A12 protein rather than the calcitermin fragment specifically, this is relevant to calcitermin's biology because the S100A12 C-terminal region is likely responsible for membrane-active bactericidal effects, and P. aeruginosa is a clinically significant airway pathogen in cystic fibrosis and other chronic pulmonary diseases.

Evidence

• Primary discovery — isolation from human airway secretions. Cole and colleagues (2001) used bioactivity-guided HPLC fractionation of human bronchoalveolar lavage fluid to isolate a peptide with antibacterial and antifungal activity. Mass spectrometry and Edman sequencing identified the 14-aa sequence VSISRSELDTINQK as the C-terminal fragment of S100A12. The study demonstrated microbicidal activity against Staphylococcus aureus, Escherichia coli, and Candida albicans at concentrations relevant to in vivo airway fluid chemistry, and placed the peptide in the context of S100-family antimicrobial defense (Cole et al., FEBS Letters 2001).

• Membrane interactions of intact S100A12 as context for calcitermin mechanism. Garcia and colleagues (2013) characterized the membrane-binding properties of intact S100A12 using biophysical approaches (circular dichroism, solution NMR, fluorescence), demonstrating that S100A12 undergoes structural changes upon membrane interaction compatible with membrane-active antimicrobial mechanisms. While the study addressed the intact protein rather than the calcitermin fragment, the membrane interaction data provide the structural framework for understanding how the calcitermin sequence — the C-terminal region of S100A12 — mediates antimicrobial killing through direct lipid bilayer disruption rather than receptor engagement (Garcia et al., PLoS ONE 2013).

• S100A12 antimicrobial activity extended to biofilm-forming clinical pathogens. Mishra and colleagues (2022) demonstrated that S100A12 inhibits the growth of Pseudomonas aeruginosa, reduces its biofilm formation, and suppresses pyoverdine secretion. The study confirmed S100A12's broad-spectrum antimicrobial activity beyond the gram-positive and Candida targets characterized in 2001, and identified mechanistic links between the protein's calcium-binding properties and its antimicrobial spectrum. These findings are contextually relevant to calcitermin's biological function in airway defense, since P. aeruginosa is a major pathogen in CF lung disease where neutrophil-derived peptides are prominent (Mishra et al., Microbial Pathogenesis 2022).

• Human: No clinical trials for calcitermin as a therapeutic agent. ClinicalTrials.gov returns 0 results for "calcitermin." S100A12 appears as a biomarker endpoint in clinical inflammatory disease studies, but these measure intact S100A12 protein rather than the calcitermin peptide fragment and do not represent therapeutic use of calcitermin.

Myths and misconceptions

• "Calcitermin is part of calprotectin." Calprotectin is the S100A8/S100A9 heterodimer — a complex of two different S100 proteins. Calcitermin derives from S100A12 (calgranulin C), which is a distinct S100 family member encoded by a different gene. All three proteins (S100A8, S100A9, S100A12) are neutrophil-derived inflammatory markers measured in clinical fecal and serum biomarker assays, which contributes to confusion. Calcitermin is specifically from S100A12, not from calprotectin's S100A8 or S100A9 components.

• "S100A12 high levels mean calcitermin antimicrobial activity is high." S100A12 as measured in clinical biomarker assays (serum, fecal) reflects intact S100A12 protein levels, not calcitermin levels. Calcitermin is a proteolytic processing product from S100A12; whether S100A12 is processed to calcitermin in a given biological context depends on local protease activity, calcium concentration, and the inflammatory microenvironment. High serum S100A12 as a biomarker of disease activity is a separate measurement from any assessment of calcitermin generation or antimicrobial function.

• "Calcitermin's function overlaps with defensins because both are cationic airway AMPs." Calcitermin and defensins (α-defensins, β-defensins) are found in similar airway compartments but are structurally and mechanistically distinct. Defensins are typically cyclic disulfide-bonded peptides with defined β-sheet antimicrobial structure; calcitermin is a linear 14-aa peptide from an S100 protein C-terminal domain with no disulfide bonds. Their antimicrobial spectra and concentrations in airway fluid differ. Both contribute to innate airway defense as part of a redundant antimicrobial shield, but they are not interchangeable pharmacological or structural entities.

Common questions

Q: Why does a structural calcium-binding protein like S100A12 have antimicrobial activity? S100A12 and related S100 proteins have positively charged C-terminal regions that are exposed when calcium is bound, creating a surface capable of interacting with negatively charged bacterial and fungal membranes. The antimicrobial activity is essentially a secondary consequence of the physical chemistry of the calcium-bound form — the C-terminal domain's amphiphilicity and cationic charge confer membrane-active properties. This pattern is seen across multiple S100 proteins and their processing products (including chromogranin A-derived peptides like vasostatin-1/chromofungin), suggesting that the calcium-binding protein scaffold commonly yields antimicrobial sequences at its termini as an evolutionary coincidence or low-cost redundancy in innate defense.

Q: Is calcitermin relevant to cystic fibrosis or chronic lung disease? The characterization of calcitermin from bronchoalveolar lavage fluid places it in the airway context where S100A12 levels are markedly elevated in cystic fibrosis, bronchiectasis, and COPD. Whether calcitermin production and local concentrations are sufficient to contribute meaningfully to airway antimicrobial defense — or are overwhelmed by the massive microbial burden and impaired mucociliary clearance characteristic of CF — has not been directly studied. S100A12 as a biomarker of pulmonary inflammation in CF is established; calcitermin's functional contribution to CF airway defense is not quantified.

Related peptides

• Vasostatin-1 — the N-terminal fragment of chromogranin A (CHGA) with antimicrobial/antifungal activity localized to its C-terminal chromofungin subdomain; a direct structural parallel to calcitermin — both are short antimicrobial peptides derived from the terminal region of a larger calcium-binding secretory protein expressed in myeloid/neuroendocrine cells
• Gramicidin D — a 15-aa antimicrobial peptide from Brevibacillus brevis; unlike calcitermin (endogenous, airway context), gramicidin D is a bacterially produced antibiotic with an approved topical clinical application, illustrating the contrast between endogenous AMPs and clinically developed microbial AMPs
• Pancreastatin — another peptide derived from a non-classical prohormone precursor (CHGA) with distinct function from the intact protein; the CHGA→pancreastatin and S100A12→calcitermin patterns both illustrate how structural/storage proteins can yield bioactive processed fragments